Abstract
Aims: To examine the long-term persistence and safety of the non-vitamin K antagonist oral anticoagulants (NOAC); dabigatran (D), rivaroxaban (R) and apixaban (A) in patients with non-valvular atrial fibrillation (AF) treated in the framework of a well-structured, nurse-based AF unit for initiation and follow-up of NOAC.Methods: Retrospective clinical data were collected for 766 consequent patients from a single cardiology outpatient clinic incorporating the AF unit.Results: The follow-up time was 367 days (183-493) for D patients, 432 days (255-546) for R patients and 348 days (267-419) for A patients. No significant differences were found between the three groups in regards to age, sex, renal function, or CHA2DS2-VASc score. For all bleeding events the incidence rates per 100 patient-years of follow-up (95% Confidence Interval (CI), p-value) were reported more often for treatment with R (17.2, 12.7-22.8) than for D (7.0, 4.0 - 11.3, p=0.001), and A (8.7, 5.2-13.6, p=0.013). The differences remai...

This publication has 17 references indexed in Scilit: